Featured Articles

  1. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

    Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

  2. A Custom Path To The Clinic: Inside A Collaborative Model 6/19/2026

    Balancing speed, compliance, and control is no small task. A different approach to external support is emerging—one that prioritizes knowledge transfer, collaboration, and long-term confidence.

  3. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.

  4. The Scale-Up Of A Transient rAAV8 Production Process 6/18/2026

    New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

  5. FDA's New Flexible CMC Framework For CGT 4/14/2026

    The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.

  6. Cost Modeling Analysis Of AAV And LV Manufacturing 3/31/2026

    Manufacturing scale plays a critical role in viral vector economics. Compare AAV and LV production scenarios to gain insight into how intermediate-scale strategies can reduce cost and risk.

  7. Why Choose A Modular Automated Approach To CAR T Manufacturing? 2/24/2026

    Get a clear, data-driven look at the biggest pressure points in cell therapy manufacturing. Explore the trends shaping today’s production challenges and where new opportunities are emerging.

  8. The New Economics Of Cell Therapy Manufacturing 2/24/2026

    Cell therapy’s future hinges not just on scientific progress but on scalable manufacturing. Explore why reliability and productivity now shape viability and how modernizing operations can support growth.

  9. Purification And QC Of An RNA 21‑Mer Oligonucleotide Via LC‑MS 1/27/2026

    Learn how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.

  10. Scalable, Sustainable Support For Next‑Gen Primer Systems 1/27/2026

    Explore how an optimized solid‑support design enables higher synthesis scales, steadier pressures, and lower solvent use while preserving yield and purity across diverse oligonucleotide lengths.